[Migraine and depression: an important relationship]

Migraine and depression are common comorbid conditions due to various factors, including genetic predisposition, neurotransmitter imbalances, hormonal fluctuations, and shared environmental exposures. Additionally, neuropeptides such as calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) play critical roles in the pathophysiology of migraine and the onset of mood disorders. The concurrent presence of migraine and depressive disorders in an individual often results in a more severe clinical progression for both conditions, thereby underscoring the necessity for routine screening of depressive symptoms during neurological evaluations. It is important to recognize that depression may manifest as either unipolar or bipolar, each requiring specific therapeutic strategies and potential referral to a psychiatrist. The selection of treatment for individuals with both migraine and depression poses significant challenges. Certain medications that are designed to alleviate migraine may exacerbate depressive symptoms, while others, although effective for both conditions, may be poorly tolerated. Consequently, targeted migraine therapy constitutes a vital component of the treatment strategy for this patient population.